BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Rifaximin SSD readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Rifaximin SSD\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06718686-11369@assetmemo.bio
DTSTAMP:20261121T004120Z
DTSTART;VALUE=DATE:20271030
DTEND;VALUE=DATE:20271031
SUMMARY:Rifaximin SSD: Phase 1/2 readout est. (NCT06718686)
DESCRIPTION:Rifaximin SSD\, phase 1/2.\nStudy: Rifaximin SSD in Dementia Tr
 ial\nEstimated primary completion: 30 October 2027. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/rifaximin-ssd#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT06718686
URL:https://assetmemo.bio/drug/rifaximin-ssd#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
